Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Immunotherapy × olaparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 41 Breast Neoplasms 34 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Neoplasms 11 Fallopian Tube Neoplasms 10 Endometrial Neoplasms 10 Pancreatic Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Recurrence 7 Neoplasm Metastasis 5 Carcinoma, Ovarian Epithelial 5 Sarcoma 4 Lung Neoplasms 4 Glioma 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Solid Tumor 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Carcinoma, Non-Small-Cell Lung 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Neuroendocrine Tumors 2

Interventions

tremelimumab 1 olaparib 1 durvalumab 1 Immunotherapy, Adoptive 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04169841 2024-02-13

GUIDE2REPAIR

Centre Georges Francois Leclerc

Phase 2 Active not recruiting

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡